CureVac NV (MIL:1CVAC)
€ 2.944 0.144 (5.14%) Market Cap: 682.36 Mil Enterprise Value: 167.57 Mil PE Ratio: 5.46 PB Ratio: 0.85 GF Score: 41/100

CureVac NV Updates On Clinical Trial - Corporate Call Transcript

Jun 17, 2021 / 12:00PM GMT
Operator

Greetings, and welcome to results of the second interim analysis of CureVac's Pivotal Phase IIb/III HERALD Study. (Operator Instructions) Please note, this conference is being recorded. At this time, I'll turn the conference over to Sarah Fakih, Head of Corporate Communications and Investor Relations. Please go ahead.

Sarah Fakih
CureVac N.V. - VP of IR

Thank you. Good morning, good afternoon, and welcome to our conference call. My name is Sarah Fakih, and I'm the Vice President of Corporate Communications and Investor Relations at CureVac. Please let me introduce today's speakers. On the call with me are Franz Haas, the Chief Executive Officer of CureVac; Ulrike Gnad-Vogt, our Interim Chief Development Officer; and Mariola Fotin-Mleczek, CureVac's Chief Technology Officer. Pierre Kemula, Chief Financial Officer, will be available for the Q&A session after the presentation.

Please note that this call is being webcast live and will be archived on the Events and Presentations section under Investor Relations on our website. Before we begin, a few

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot